Susanna M. Nazarian, Ph.D.
Affiliations: | 2009 | Johns Hopkins University, Baltimore, MD |
Area:
Medicine and Surgery, Public Health, Biostatistics BiologyGoogle:
"Susanna Nazarian"Cross-listing: PHTree
Parents
Sign in to add mentor| Francesca Dominici | grad student | 2009 | Johns Hopkins | |
| (Predictors of early saphenous vein graft patency, platelet hyper-reactivity and aspirin-insensitive thromboxane generation in patients undergoing coronary artery bypass graft surgery.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Limaye AP, Rahnemai-Azar AA, Nazarian SM, et al. (2021) Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients. Transplantation Direct. 7: e637 |
| Limaye AP, Rahnemai-Azar AA, Nazarian SM, et al. (2021) Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients. Transplantation Direct. 7: e637 |
| Ramadan OI, Naji A, Levine MH, et al. (2020) Kidney transplantation and donation in the transgender population: a single-institution case series. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons |
| Nazarian SM, Peng AW, Duggirala B, et al. (2017) The Kidney Allocation System Does Not Appropriately Stratify Risk of Pediatric Donor Kidneys: Implications for Pediatric Recipients. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons |
| Kakouros N, Nazarian SM, Stadler PB, et al. (2016) Risk Factors for Nonplatelet Thromboxane Generation After Coronary Artery Bypass Graft Surgery. Journal of the American Heart Association. 5 |
| Berli JU, Montgomery JR, Segev DL, et al. (2015) Surgical management of early and late ureteral complications after renal transplantation: techniques and outcomes. Clinical Transplantation. 29: 26-33 |
| Nazarian SM, Misch EA, Rakita RM, et al. (2014) Optimal immunosuppression for HIV-positive kidney transplants: long-term randomized controlled trials needed. Transplantation. 97: e70 |
| Bagnasco SM, Zachary AA, Racusen LC, et al. (2014) Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients. Transplantation. 97: 440-5 |
| Sharif A, Kraus ES, Zachary AA, et al. (2014) Histologic phenotype on 1-year posttransplantation biopsy and allograft survival in HLA-incompatible kidney transplants. Transplantation. 97: 541-7 |
| Lonze BE, Zachary AA, Magro CM, et al. (2014) Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 14: 459-65 |